‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK

Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J unit targets former employee over alleged mass data theft

17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

Americas

Astellas blocks generic version of key urology drug until 2030

12 March 2026 The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.

More features

US firm boosts patent bench with Desmarais hire

J&J unit targets former employee over alleged mass data theft

HSF Kramer hires patent litigator as partner in Germany

INTA: ‘New normal’ for in-house counsel as budgets fall

Mylan withdraws defence claims against Novo in Wegovy dispute

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK

More on this story

Editor's picks

Editor's picks

More features